Cited by — Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial.
No admitted local citation edges point to this work yet.
